Fed. Circ. Won't Block Amgen's Herceptin Biosimilar
The Federal Circuit on Friday shot down Genentech's latest attempt to block Amgen from selling a biosimilar version of its blockbuster cancer drug Herceptin....To view the full article, register now.
Already a subscriber? Click here to view full article